|Bid||62.50 x 800|
|Ask||63.99 x 3100|
|Day's Range||63.45 - 63.67|
|52 Week Range||48.58 - 65.90|
|PE Ratio (TTM)||121.74|
|Earnings Date||Oct 16, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||1.12 (1.73%)|
|1y Target Est||71.00|
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.
In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018.
During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%.
In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
- FDA approval of new software upgrade for Abbott's deep brain stimulation therapy enables advanced, patient-centric features for people living with Parkinson's disease and essential tremor - New Informity™ ...
Shares of automotive companies climbed last Thursday as U.S. President Donald Trump eased the car tariff threat following a meeting with European Commission President Jean-Claude Juncker.
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
During Abbott Laboratories’ (ABT) second-quarter earnings release on July 18, the company increased its fiscal 2018 guidance. This move was triggered by the company’s strong performance in the quarter. ABT stock rose ~3.1% on the day of its earnings announcement.
As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018. Of the ten analysts tracking DaVita, five recommend “strong buy,” four recommend “hold,” and one recommends “sell.”
Abbott Laboratories’ (ABT) Diabetes segment registered second-quarter sales growth of ~40.0%, reaching $470.0 million. The Diabetes segment’s strong performance was driven by the continued uptake of Abbott’s Freestyle Libre CGM (continuous glucose monitoring) device. The device was approved by the FDA in September 2017. Abbott Laboratories gained market share in the second quarter in the diabetes market space from competitors such as Medtronic (MDT) and Dexcom (DXCM) due to the strong momentum in its Freestyle Libre adoption.
Q2 Results: What Drove Its Robust Growth? Abbott Laboratories (ABT) reported robust second-quarter revenues in its Medical Devices segment, as we discussed in the previous article. ABT’s heart failure and neuromodulation sales rose ~1.0%, and ~5.8%, respectively, in the second quarter on an organic basis.
Q2 Results: What Drove Its Robust Growth? The Medical Devices segment’s sales registered YoY (year-over-year) growth of ~11.3% on a reported basis. On an organic basis, the segment’s sales were up ~8.2%.
Over the last few days, we have heard and seen all sorts of creative investment basket acronyms in the tech sector from FAANG to FAANGMA, or the new AGMA (ok, I just made that one up). It does not change the fact that everyone and their mom was invested in the tech sector, given its phenomenal growth of around 30% in large-cap companies of about $100 billion or larger. Netflix dropped 15% on weak subscriber numbers.
In the second quarter, Abbott Laboratories (ABT) reported sales of $1.9 billion in its Nutrition business, which contributed ~24.0% to the company’s total sales of $7.8 billion in the quarter. The Nutrition segment’s sales registered YoY (year-over-year) growth of ~7.3% on a reported basis. In the second quarter, Abbott Laboratories’ international nutrition sales came in at $1.1 billion, up ~12.5% on a YoY basis.
Q2 Results: What Drove Its Robust Growth? The Established Pharmaceuticals segment sales registered YoY (year-over-year) growth of ~10.5% on a reported basis. Foreign exchange had a negative impact of ~1.8% on the business.
In the second quarter, Abbott Laboratories (ABT) reported sales of $1.9 billion in its Diagnostics business, which contributed ~24.0% to the company’s total sales of $7.8 billion in the quarter. The Diagnostic segment’s sales registered YoY (year-over-year) growth of ~47.2% on a reported basis. On an organic basis, the segment’s sales were up ~6.6%.
This places Via Christi — and Wichita for that matter — on the leading edge of a technology that eventually could be taken to market and possibly become a standard of care in cardiology.
ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ -- Abbott (ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott.